@FierceBiotech: Dana-Farber researchers highlight progress with new drugs for acute myeloid leukemia. FierceBiotechResearch article | Follow @FierceBiotech
@JohnCFierce: Eyeing pivotal PhIIIs, Margolin nabs $53M crossover round for Allena. News | Follow @JohnCFierce
@DamianFierce: "You know, at the right price these guys basically will do anything." More from Bloomberg | Follow @DamianFierce
> Alnylam's ($ALNY) Chief Human Resources Officer Karen Anderson tells The Boston Globe that the biotech is planning on recruiting close to 1,500 new staffers in the next 5 years, including a batch of workers from the hundreds being laid off at Biogen's ($BIIB) Boston facilities. "I don't want the same people that Pfizer ($PFE) wants," she says. "I need people who are ready for a risk." Story
> Catabasis Pharmaceuticals ($CATB) kicked off a Phase IIa trial of its treatment for high cholesterol, enrolling about 150 patients to test how well its oral therapy can reduce LDL cholesterol. More
> The growing scourge of non-alcoholic steatohepatitis, or NASH, has spurred a bevy of drugmakers into a race to develop the first approved treatment for the liver disease. Feature
Medical Device News
@FierceMedDev: Scientists roll out 3-D printed self-assembling blood vessels. Article | Follow @FierceMedDev
@EmilyWFierce: Pharma ad budgets stay flat, even as spending jumps across the board: Report. FiercePharmaMarketing story | Follow @EmilyWFierce
> Illumina Accelerator discloses its latest funded class of four genomic startups. Story
> Top gynecologists push back at FDA crackdown on power morcellator devices. Report
> Chemotherapy cooling cap to reduce hair loss for breast cancer patients gets FDA nod. Article
Pharma News
@FiercePharma: Allergy Therapeutics brings long-delayed grass allergy vax into PhII. FierceVaccines story | Follow @FiercePharma
@CarlyHFierce: ICYMI: AbbVie's Imbruvica, Amgen's Kyprolis shine at annual ASH meeting. More | Follow @CarlyHFierce
> Lilly's split of animal and human drug production does not bode a spinoff, execs insist. Report
> Advera: Harvoni bests Sovaldi, Viekira Pak in hep C drug safety. Article
Biotech Research News
> New screening tech at Scripps spotlights diabetes drug candidates. Item
> Dana-Farber researchers highlight progress with new drugs for acute myeloid leukemia. More
> Imperial College scientists engineer a CRISPR/Cas9 breakthrough on malaria. Report
> Florida U team's gene therapy safeguards cognition in rats. Story
> Epilepsy scientific meeting highlights promise of cannabidiol for reducing seizures. Article
Pharma Marketing News
> Can new PhIII data help Gilead's Zydelig stage a comeback in CLL? Article
> Pharma ad budgets stay flat, even as spending jumps across the board: Report. More
> Gilead's Harvoni beats Sovaldi, AbbVie's Viekira Pak in hep C drug safety: Advera. Story
> Cancer-free President Carter notes Keytruda treatment: Will the celebrity effect kick in? More
> With Paris spotlight on climate change, here's how Big Pharma stacks up. Article
Vaccines News
> Second flu shot helps cancer patients stave off infection, Yale team says. Item
> Japan's Kaketsuken covered up illicit blood product, vaccine production methods for 40 years. More
> Cerberus Capital management invests $105M in PaxVax. Report
> Allergy Therapeutics brings long-delayed grass allergy vax into PhII. Story
> U.S. Army, Hawaii Biotech join for dengue vaccine effort. Article